Press Releases

Biothera Immunotherapy Combination Results in Tumor Reduction During Maintenance Phase of Non-Small Cell Lung Cancer Study

GENEVA — April 15, 2015 — The combination of the investigational cancer immunotherapy Imprime PGG and the monoclonal antibody bevacizumab achieved additional meaningful reductions in tumor burden during the maintenance phase of Biothera’s recent phase 2 clinical trial in non-small cell lung cancer (NSCLC). The new data will be released today at the European Lung Cancer Conference. Biothera conducted a randomized Phase 2 clinical study...

Read More

Biothera to Present Three Late-Breaking Posters at the American Association for Cancer Research Annual Meeting

EAGAN, MN — April 9, 2015 — Biothera scientists will present four scientific posters at the world’s largest annual cancer research conference: the American Association for Cancer Research (AACR) annual meeting April 18-22 in Philadelphia. Three of the posters were selected for the high profile, late-breaking research sessions—sessions devoted to the newest, most exciting research of the year. “We are excited to present the latest...

Read More

Biothera to Participate in Novel Immunomodulatory Therapies Panel Discussion at Cancer Progress Conference

EAGAN, MN — March 16, 2015 — Ada Braun, M.D., Ph.D., Chief Medical Officer for Biothera’s Pharmaceutical business, will participate in an expert panel discussion of novel immunomodulatory therapies tomorrow at the 26th Annual Cancer Progress Conference in New York, NY. The panel will include leading clinicians and researchers from major pharmaceutical companies focused on new therapies that engage the immune system to fight cancer....

Read More

Biothera’s Investigational Cancer Immunotherapy Imprime PGG Neutralizes Cancer Defense Mechanisms in the Tumor Microenvironment

New Preclinical Data to be presented today at Keystone Symposium in Montreal EAGAN, MN, March 9, 2015 — New preclinical research from Biothera further demonstrates the ability of its cancer immunotherapy drug candidate Imprime PGG® to initiate a cascade effect of immune responses that neutralize cancer-associated immunosuppression in the tumor microenvironment. Biothera will present the new data today in Montreal at the Keystone Symposium: Dendritic...

Read More

Biothera Immunotherapy Binds to Multiple Immune Cell Receptors to Kill Cancer

Researchers to Present New Data at Keystone Symposia on Tumor Immunology EAGAN, MN, February 10, 2015 — Biothera’s late stage cancer immunotherapy drug binds to multiple innate immune cell receptors to exert enhanced cytotoxicity against tumor cells. Researchers will present new data showing Imprime PGG® binds to Fc gamma receptors (FcγR) in addition to complement receptor 3 (CR3) on human neutrophils and monocytes at a...

Read More

Page 6 of 6« First...23456